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Abstract
Three autogenous vaccine trials were carried out on farms where Mycoplasma bovis had been identified as a major pathogen. The first trial was carried on a veal farm in 
the Lombardia region of northern Italy. Vaccine, prepared by saponising an M bovis strain taken from the farm some months before, was given as single inoculation 
to 24 calves on arrival while 19 were left unvaccinated. Six months later calves were sent to the abattoir where lungs were examined for gross pathological lesions. The 
mean weight of the vaccinated group was higher though not significantly so and mean lesion scores were similar; however the percentage of vaccinated calves with 
severe lung lesions and pleuritis was lower than in the non vaccinates. A second trial was carried out in northern England on a farm where monthly batches of male 
calves from a nearby dairy herd were reared under a feedlot system. One group of 27 calves were vaccinated with a saponised strain of M bovis isolated from the lungs 
of a pneumonic calf on the farm prior to the start of the trial. A second batch of 25 calves was left unvaccinated. The groups of calves were monitored for nine months 
prior to slaughter and records kept of antibiotic usage and mortality. The mortality rates in the vaccinated calves were about 15% compared to 28% in unvaccinated 
calves; however there was no difference in the number of times calves were treated for respiratory disease. A third batch of calves, treated with oxytetracycline on 
arrival because a number were already showing respiratory signs, had a lower mortality rate and fewer subsequent treatments. A third trial was carried out on a milk 
veal unit in the Veneto region of Italy. A group of 19 calves were vaccinated on arrival with a saponised isolate taken earlier from the farm; a similar number of calves 
of the same batch were left unvaccinated. After 6 months animals were routinely processed at the abattoir and lungs inspected. Results showed that vaccinated calves 
had higher mean body weights and although similar mean lung scores there was a smaller percentage of vaccinated calves with severe lung lesions and pleuritis.
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Introduction
Mycoplasma bovis is a major cause of respiratory disease, mastitis 
and arthritis in cattle.  Having first been isolated in 1961 in the USA 
from a case of severe mastitis in cattle [1], M. bovis has now spread 
via animal movements or products throughout the world including all 
European countries and most recently to Finland and New Zealand [2]. 
In Europe, M. bovis is responsible for at least a quarter of losses due 
to calf pneumonia although this is probably an underestimate as few 
laboratories routinely monitor for mycoplasmas [1].
The inability of antibiotics to control bovine mycoplasmosis 
caused by M. bovis has focused attention on vaccines as a more 
sustainable and cost effective solution and critically reducing threat 
of antimicrobial resistance [3]. However many experimental vaccine 
studies have proved ineffective or even damaging to affected calves so 
consequently it is unlikely that a commercial vaccine will appear in 
Europe in the next few years. In the USA a number of vaccines have 
been used in cattle but there is no published evidence that they are 
effective [3].  
Under experimental conditions, an M. bovis vaccine inactivated 
by saponin was shown to be safe, immunogenic and protective to 
challenge by a heterologous strain [4]. Attempts to commercialise 
the vaccine are on-going but in the meantime it has been possible to 
evaluate autogenous vaccines, using saponin both as an inactivant and 
adjuvant, from isolates taken and used on individual premises.  
Material and method
Vaccine production
Strains of M. bovis were isolated from lungs and grown in 
mycoplasma medium for 3 days at 38.5oC and then subcultured 
in fresh medium for a further 2 days [4].  The mycoplasmas were 
centrifuged at 10,000g for 30 minutes, resuspended and washed once 
in 0.1M phosphate buffered saline (pH 7.2).  Cells were centrifuged 
again and resuspended in 1/50th of the original volume.  To the 
washed cells was added 2mg/ml of filter sterilised saponin (Sigma, 
Poole) and incubated for one hour at 38.5oC.  The saponised cells 
were then placed at 4oC.  The titre of the washed cells was adjusted 
to 108 colony forming units (CFU) /ml and protein content estimated 
at approximatel 2mg/ml.  The vaccine was plated onto blood agar to 
check for bacterial contamination and into mycoplasma medium to 
ensure inactivation of mycoplasmas.  
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Experimental design
Three autogenous vaccine trials were conducted on farms 
experiencing bovine mycoplasmosis caused by M. bovis. Routine 
vaccination for other respiratory pathogens was also carried out. 
Evaluation of the effects of the vaccine on the different farms varied. 
In trials 1 and 3 it was based on a comparison of lung lesions between 
vaccinated and unvaccinated calves at post mortem examination; and 
in trial 2 it was based on mortality and antibiotic treatment records 
between groups of vaccinated and unvaccinated calves. No attempt was 
made to alter the management of the farms during the trials
Trial 1
Mycoplasma bovis was isolated and identified from the lungs of 
a 3-month-old calf which had died of pneumonia on a farm of veal 
calves in Lombardy, northern Italy with a history of respiratory disease. 
The affected lung consisted of congested apical lobe which contained 
caseous necrotic lesions which is pathognomic for M. bovis. An 
inactivated vaccine was produced by growing the isolate in mycoplasma 
medium and inactivating the washed antigen in saponin as described 
above. Alternate calves of 2-4 weeks of age were vaccinated with single 
1ml dose of vaccine on arrival. In total 19 were vaccinated and 24 were 
unvaccinated. Serum samples were taken 4 weeks after vaccination. 
After 6-7 months all calves were weighed and sent to slaughter where 
lungs were inspected and scored as previously described where 0=non 
pneumonic; 1= mild pneumonic lesion; 2=moderate pneumonic lesion; 
and 3=severe pneumonic lesion [5].
There was poor serum conversion in vaccinated calves with only 
60% obtaining satisfactory antibody levels 4 weeks after vaccination.  The 
results from the experiment showed that vaccinated calves had slightly 
lower lung scores than unvaccinated calves with a lower percentage 
of vaccinated calves having significant lesions (Table 1); the number 
of calves with pleuritis was also significantly lower in the vaccinated 
group than the non vaccinates.  The mean body weights were slightly, 
though not significantly higher, in the vaccinated groups. There was no 
mortality in calves from either the vaccinated or vaccinated groups.
While all calves had seroconverted to M bovis antibody by the end 
of the experiment, it was interesting that the caseous necrotic lesions 
associated with severe mycoplasmosis were not seen in the calves at 
post-mortem examination. Indeed, respiratory disease during this 
winter was unusually mild. Antibody to RSV and PI3 were detected in 
some cattle but were more likely associated with vaccine antibody for 
which the calves had been vaccinated. 
Trial 2
A farm in northern England which fattened male calves obtained 
from a nearby dairy herd was identified as a site for a vaccination trial. 
The farm had previously used an inactivated vaccine made by AHVLA, 
UK which had resulted in lower mortality rates and treatment costs 
compared to previous years [1]. However, the owner stopped using the 
vaccine and mortality rates increased: typically, 25% of each monthly 
batch of approximately 20-25 calves. It was clear from observing 
successive batches of male calves that a number arriving from the dairy 
farm were already affected with respiratory disease from which M bovis 
could be detected. 
In this trial, an isolate from the lung of a calf with severe caseous 
necrotic pneumonia on the farm was obtained and an inactivated 
vaccine was produced as described above: batch 1 consisting of 25 calves 
were left unvaccinated and acted as controls; batch 2 of 27 calves were 
vaccinated on arrival with 1ml of vaccine. The calves were bled 4 weeks 
after vaccination to check antibody levels.  Treatments (which consisted 
of single injections of enrofloxacin or tildipirosin administered by 
the private veterinary surgeon) were recorded for individual calves 
following signs of respiratory disease; deaths too were recorded over 
the next 9 months; finally batch 3  comprising of a small group of 10 
calves, 3 of which showed signs of respiratory disease on arrival, were 
treated with oxytetracycline over two successive days following the 
manufacturer’s recommendation. The calves were then given a single 
dose of autogenous vaccine
Antibody levels were satisfactory in all vaccinated calves tested 4 
weeks later indicating high antigen content in the inactivated vaccine. 
Mortality rates were very high in the unvaccinated group of calves at 
28% (Table 2). The effect of a single vaccination was to significantly 
(p<0.01) reduce mortality by 50% but there was little difference in 
individual calf treatments with antibiotics. However, the group that 
were treated with oxytetracycline before vaccination showed fewer 
subsequent treatments and lower mortality rates, but the group was too 
small to provide any statistical significance.
Trial 3
A veal calf unit in Veneto region of northern Italy was identified as 
consistently having respiratory disease from which M bovis was shown 
to be the most persistent pathogen. In all, 19 calves were vaccinated 
on arrival with 1ml of a saponised vaccine prepared at the IZS Sicily 
(who are licensed to make autogenous vaccine) from an isolate taken 
from a calf dying of respiratory disease with characteristic lesions of M. 
bovis; 17 calves from the same batch acted as unvaccinated controls. All 
calves were housed together and bled at four weeks and the vaccinated 
calves boosted with 1ml of vaccine. After 6 months calves were sent for 
slaughter; lungs were obtained from all calves and examined and scored 
at the IZS Venezie as for trial 1. 
Seroconversion to the M bovis vaccine was not strong in the 
vaccinated calves with only 55% animals showing satisfactory levels 
after the first vaccination. However, all seroconverted after the booster 
dose. Of 17 non vaccinated calves, 6 had significant lesions (35%) and 
of the 19 vaccinated, 5 had significant lesions (26%). While mean lung 
scores were similar, there were significantly fewer cattle (p <0.01) with 
pleuritis in the vaccinated group. The mean weight of the vaccinated 
calves was also significantly higher than the non-vaccinates (Table 3).
Group No Mean lung score* 
No of calves with 
significant lesions 
(>1)* /(%)
No with 
pleuritis/ 
(%)
Mean 
weight
Non vaccinated 19 0.8  8 (42) 16 (84)** 154.9
Vaccinated 24 0.6  8 (33) 12 (50) 155.2
Table 1. Trial 1: Summary of results of autogenous vaccine trial in veal calf unit (Lombardy, 
Italy)
* Radaelli et al., 2008
** p <0.01
Group Batch No No calves treated/ (%)
No of 
treatments Deaths/%
Non 
vaccinated B1 25 14 (56) 28 7 (28)
Vaccinated B2 27 15 (55.6) 30 4 (14.8)*
Treated/
vaccinated B3 10 4 (40%) 7 1 (10%)
Table 2. Trial 2: Summary of results of autogenous vaccine trial in calf rearing unit 
(Northern England)
* total antibiotic treatments for respiratory disease (often including the same calf) during 
trial
** p<0.05
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Discussion
The aim of these trials was to see the effect of an autogenous vaccine 
for M. bovis in real farm settings. There were a number of factors which 
were not possible to control e.g. the weather and the degree and nature 
of infection to which the calves were exposed. In fact, the weather 
during trial 1 was very mild and infection was not severe although all 
calves were exposed to infection as measured by serological test. There 
was however significant evidence to show that the vaccine had some 
beneficial effects in terms of a reduction in the number of calves with 
severe lesions despite little difference in mean finishing weights.  
Trial 3 which took place on another Italian veal farm had similar 
results in terms of a reduction in number of calves showing severe 
lesions and pleuritis. Although it is difficult to compare results on the 
two different farms, giving a second dose of vaccine did not bring about 
any obvious improvements. It could however have compensated for the 
reduced antigen content of the vaccine prepared in Italy as only just over 
half of the vaccinated group seroconverted after primary vaccination. 
Trial 2 took place on a male calf rearing unit with annual mortality 
rates regularly reported up to 30%. It was apparent that the nearby dairy 
farm from which the calves were sourced was affected with M bovis as 
clinical disease was evident in 10-30% of animals arriving on the feed 
lot in the monthly batches.  However, the effect of a single vaccination 
on the calves on arrival was to reduce the mortality rate to nearly half 
compared to the non vaccinates clearly showing that M bovis was 
the major pathogen here. A small sub trial in which all calves (some 
of which were showing early signs of pneumonia) were treated with 
oxytetracycline on arrival before vaccination gave some encouraging 
results in terms of reduced subsequent treatments and lower mortality 
rates. However, it should be noted that some M. bovis strains have 
shown in vitro resistance to this and other antibiotics, so susceptibility 
testing is recommended before treatment [6]. Further reduction in the 
mortality and treatment rates on this farm can only be brought about 
by tackling the health issues on the dairy herd from which the calves 
originated as it is unlikely that a vaccine against M. bovis can fully be 
fully protective in the face of this persistent challenge.
In conclusion it is important to recognise that this autogenous 
vaccine works optimally where M bovis is the sole or major pathogen 
causing respiratory disease in a herd, so accurate laboratory diagnosis is 
necessary prior to vaccine use. In addition, these results show that this 
vaccine works optimally when given to young calves on arrival at the 
farm reducing mortality rates and treatment costs. Antibiotic treatment 
of calves on arrival (which is normal practice on many farms to offset the 
stress of animal movements) should also be considered as many calves 
may already be showing disease signs.  Finally, we recommend that 
the M. bovis vaccine should eventually be included in the multivalent 
vaccines that are currently used to combat respiratory infections. 
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Group No Mean lung score*
No of calves with 
significant lesions 
(>1)* (%)
No with 
pleuritis 
(%)
Mean 
weight
Non vaccinated 17 0.65 6  (35) 9 (53)** 130.5
Vaccinated 19 0.63 5  (26) 5 (26) 136.1**
Table 3. Trial 3: Summary of results of autogenous vaccine trial in veal calf unit (Veneto, 
Italy)
* Radaelli et al.
** P<0.01
